Weiss Ratings Reiterates Sell (E+) Rating for 60 Degrees Pharmaceuticals (NASDAQ:SXTP)

60 Degrees Pharmaceuticals (NASDAQ:SXTP)‘s stock had its “sell (e+)” rating reissued by Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.

Other research analysts have also recently issued research reports about the stock. HC Wainwright restated a “neutral” rating on shares of 60 Degrees Pharmaceuticals in a report on Friday, March 28th. Ascendiant Capital Markets upped their price target on 60 Degrees Pharmaceuticals from $5.80 to $7.00 and gave the stock a “buy” rating in a research note on Monday, June 2nd.

60 Degrees Pharmaceuticals Price Performance

Shares of 60 Degrees Pharmaceuticals stock opened at $2.28 on Wednesday. 60 Degrees Pharmaceuticals has a 1 year low of $1.41 and a 1 year high of $35.99. The firm has a market cap of $3.36 million, a PE ratio of -0.23 and a beta of 2.89. The company has a 50 day simple moving average of $2.64 and a two-hundred day simple moving average of $3.57.

60 Degrees Pharmaceuticals (NASDAQ:SXTP) last issued its earnings results on Thursday, May 15th. The company reported ($1.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.31) by ($0.25). The business had revenue of $0.18 million during the quarter, compared to analyst estimates of $0.15 million. As a group, research analysts anticipate that 60 Degrees Pharmaceuticals will post -5.09 earnings per share for the current year.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.